Kura Oncology (NASDAQ:KURA - Get Free Report) will be releasing its earnings data after the market closes on Thursday, May 2nd. Analysts expect Kura Oncology to post earnings of ($0.56) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same quarter last year, the business earned ($0.49) earnings per share. On average, analysts expect Kura Oncology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Kura Oncology Stock Performance
NASDAQ KURA traded up $0.65 during trading on Friday, reaching $19.65. The company's stock had a trading volume of 576,891 shares, compared to its average volume of 1,327,806. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.26 and a current ratio of 12.26. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -9.45 and a beta of 0.85. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The business's fifty day moving average price is $20.67 and its 200-day moving average price is $15.46.
Insider Buying and Selling
In related news, SVP Thomas James Doyle sold 2,318 shares of the business's stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $41,260.40. Following the sale, the senior vice president now owns 48,093 shares of the company's stock, valued at $856,055.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Kura Oncology news, COO Kathleen Ford sold 1,496 shares of the company's stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $26,628.80. Following the sale, the chief operating officer now owns 21,602 shares of the company's stock, valued at $384,515.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 2,318 shares of the company's stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $41,260.40. Following the completion of the sale, the senior vice president now directly owns 48,093 shares in the company, valued at approximately $856,055.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,867 shares of company stock valued at $104,433. Corporate insiders own 5.50% of the company's stock.
Analyst Ratings Changes
KURA has been the topic of several analyst reports. JMP Securities lifted their target price on shares of Kura Oncology from $22.00 to $32.00 and gave the company a "market outperform" rating in a report on Wednesday, January 31st. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price on shares of Kura Oncology in a report on Monday. Wedbush reaffirmed an "outperform" rating and issued a $37.00 target price on shares of Kura Oncology in a report on Wednesday, February 28th. Finally, StockNews.com downgraded shares of Kura Oncology from a "hold" rating to a "sell" rating in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $28.28.
Read Our Latest Stock Report on Kura Oncology
Kura Oncology Company Profile
(
Get Free Report)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Further Reading
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
